Using our integrated executable LC-melanoma model, we screened the negative impact of targeted drugs that would affect melanoma signaling pathways and demonstrated that the MAPK pathway inhibitors dabrafenib (mutant BRAF inhibitor), trametinib (MEK), and ulixertinib (ERK) would be detrimental to immune surveillance by reducing LC migration to LNs. This evidence concerns the gene BRAF and melanoma.